Picture supply: Getty Photos
Oxford Nanopore Applied sciences (LSE:ONT) is an thrilling FTSE 250 inventory and is massively undervalued in keeping with analysts. Nonetheless, regardless of its groundbreaking expertise and up to date collaborations, the inventory has slumped. Not like lots of its friends, the hunch truly has little or no to do with Donald Trump’s tariffs.
A DNA pioneer
For these unfamiliar, Oxford Nanopore is a pioneer in third-generation DNA sequencing expertise. The corporate’s units use nanopores — these are tiny protein-based constructions — to sequence DNA or RNA in actual time by detecting electrical adjustments as molecules move by way of these pores. This expertise is all obtainable on handheld units.
Its expertise is used throughout a number of fields, starting from infectious illness evaluation to genomic surveillance in distant areas. As an illustration, its units had been used through the Ebola outbreak in 2015 to sequence viral genomes quickly.
Nonetheless, issues haven’t gone to plan since itemizing in late 2021. Oxford Nanopore’s share worth has plummeted by over 80%, decreasing its market capitalisation to over £1bn. This dramatic decline stems from a mixture of things, together with persistent losses, heightened competitors, and macroeconomic challenges reminiscent of rising rates of interest. Analysts have additionally flagged issues about slower-than-expected progress and a worsening funding surroundings.
Analysts name this a ‘Sturdy Purchase’
Regardless of the collapsing share worth, analysts appear remarkably bullish. Of the ten analysts masking the inventory, 4 have Purchase scores and 4 have Outperform scores. What’s extra, the common share worth goal is now 69% greater than the present share worth. That is usually signal. By the way, the best share worth goal is 138% above the place we’re immediately.
Nonetheless, shrewd buyers might want to query this name. The corporate’s working loss has almost doubled to £152m since 2019, and the forecast suggests it received’t attain adjusted EBITDA breakeven till 2027. For 2025, analysts anticipated unfavorable earnings per share (EPS) of 15.9p. That’s not insignificant for inventory valued at 114p per share.
The saving grace is the web money place which at present stands at £292m and is about to fall to £158m by the tip of 2026 based mostly on the forecast. Which means it does have some runway till its long-awaited profitability.
In fact, it might not attain profitability in its present state. Ongoing losses and a falling share worth have made the inventory susceptible, with some suggesting it may turn out to be a takeover goal for bigger gamers like Thermo Fisher Scientific or Danaher.
The underside line
On 9 April 2025, Oxford Nanopore introduced a strategic collaboration with Cepheid to develop automated sequencing options for infectious ailments. The may increase into different areas like most cancers diagnostics and human genetics, doubtlessly opening new income streams.
Nonetheless, buyers must be cautious that Oxford Nanopore is a traditional high-risk, high-reward funding. Its revolutionary expertise and strategic collaborations place it effectively for future progress, however I’m reluctant to throw my very own cash behind it. Nonetheless, I’ll proceed to maintain a detailed eye on developments.
